Babuin Luciano, Scarpa Daniele, Jaffe Allan S
Department of Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy.
Department of Cardiology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Curr Cardiol Rep. 2017 Aug 24;19(10):91. doi: 10.1007/s11886-017-0903-5.
Reduction of kidney function and heart disease frequently coexisted in the seam patient. The relation between renal and heart function is quite complex and bring out some unresolved questions about diagnosis (mostly related to the biomarkers levels interpretation), pharmacological therapy (mostly related to drugs kinetics and efficacy), and non-pharmacological therapy.
Patients with kidney dysfunction (KD) are frequently excluded and underrepresented in the large trials. It is well-known that coronary revascularization reduces mortality also in KD patients presenting with acute coronary syndrome. However, acute kidney injury (AKI), primarily related at contrast medium administration, is worse prognosis. For this reason, prevention, early diagnosis, and effective therapy of ACK are key elements in assistance of these patients. In this context, recently, some new biomarkers of renal function have been proposed. Frequently, patients with acute coronary syndromes and kidney disease are undertreated, worsening their prognosis. Undertreatment and comorbidities associated with renal dysfunction explain the higher mortality of these patients.
